# Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

> **NCT02443116** · PHASE2 · COMPLETED · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 254 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **BIOLOGICAL:** NGM282
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02443116
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-31
- **Primary completion:** 2019-12-06
- **Final completion:** 2020-01-17
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443116, "Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02443116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*